Clinical characteristics and haemodynamic data at baseline

 Age years63±14
 Males94 (51)
 NYHA FC % (I/II/III/IV)1.1/35.0/59.0/4.9
 6MWD m397±117
 History of VTE135 (73)
Associated medical conditions
 Splenectomy18 (9.8)
 Pacemaker/indwelling catheter22 (12.0)
 Myeloproliferative disorder3 (1.6)
 APS7 (3.8)
Lung function tests
 TLC % pred90.7±15.2
 FVC % pred99.7±21.9
 FEV1 % pred89.1±20.1
DLCO % pred61.2±13.6
 Systolic PAP mmHg75.6±17.5
 Diastolic PAP mmHg24.5±7.4
 Mean PAP mmHg44.1±9.8
 Mean RAP mmHg8.3±4.0
 PAWP mmHg9.6±3.5
 Cardiac output L·min−14.89±1.30
 Cardiac index L·min−1·m−22.71±0.64
 PVR dyn·s·cm−5610±255
SvO2 %62.2±7.2
PAH therapy
 sGC stimulator59 (32.1)
 ERA73 (39.7)
 PDE5-I47 (25.5)
 Prostacyclin analogue13 (7.1)
 Medications % (none/single/double/triple)38.0/26.6/28.3/7.1
Indication for BPA
 Clot inaccessibility149 (81.0)
 Unfavourable risk–benefit ratio for PEA16 (8.7)
 Refusal of PEA4 (2.2)
 Post-PEA15 (8.2)

n=184. Data are presented as mean±sd or n (%), unless otherwise stated. NYHA FC: New York Heart Association functional class; 6MWD: 6-min walk distance; VTE: venous thromboembolism; APS: antiphospholipid syndrome; TLC: total lung capacity; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; DLCO: diffusing capacity for carbon monoxide; PAP: pulmonary artery pressure; RAP: right atrial pressure; PAWP: pulmonary artery wedge pressure; PVR: pulmonary vascular resistance; SvO2: mixed venous oxygen saturation; PAH: pulmonary arterial hypertension; sGC: soluble guanylate cyclase; ERA: endothelin receptor antagonist; PDE5-I: phosphodiesterase-5 inhibitor; BPA: balloon pulmonary angioplasty; PEA: pulmonary endarterectomy.